Actively Recruiting

Phase 2
Age: 45Years - 65Years
All Genders
NCT07001150

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Led by Tanta University · Updated on 2025-09-10

50

Participants Needed

1

Research Sites

55 weeks

Total Duration

On this page

Sponsors

T

Tanta University

Lead Sponsor

P

Prof. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

CONDITIONS

Official Title

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Who Can Participate

Age: 45Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 45 and 65 years old
  • Both sexes
  • Patients with Parkinson's disease on dopamine replacement therapy
  • Modified Hoehn and Yahr stage, MHY 1-4
Not Eligible

You will not qualify if you...

  • Subjects younger than 18 years of age
  • Pregnant or breastfeeding women
  • Suspected hypersensitivity to silymarin or multivitamins
  • Advanced liver disease such as ascites, bleeding esophageal varices, or hepatic encephalopathy
  • Morbid obesity with Body Mass Index (BMI) greater than 40
  • Severe illness including multisystem failure, cancer, or poorly controlled diabetes with Hemoglobin A1C (HbA1C) over 7%
  • Current use of Silymarin or use within the past two weeks
  • Other conditions judged by investigators as unsuitable for enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tanta Hospital for Mental Health

Tanta, Tanta, Qism 2, Egypt, 31511

Actively Recruiting

Loading map...

Research Team

N

Nour Elsherbeny, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here